Yingsheng Biology, a Chinese biotechnology firm that provides mass spectrometry (MS) services, announced on Wednesday that it has raised nearly RMB100 million (US$14.47 million) in a series C round of financing.
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access thousands of news articles and data posts over the past 9 years!
Already have an account or paid subscription?